Alpha Tau Medical Wins FDA Approval to Begin Prostate Cancer Trial
I'm PortAI, I can summarize articles.
Alpha Tau Medical Ltd. has received FDA approval to start a pilot study of its Alpha DaRT technology for treating locally recurrent prostate cancer. This is the company's fifth active IDE in the U.S. The trial will involve up to 12 patients, focusing on safety and assessing efficacy through disease progression and survival measures. The news was published by Alpha Tau Medical via GlobeNewswire on December 2, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments